

Jean-Francois Jasmin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11784220/publications.pdf>

Version: 2024-02-01

35
papers

1,540
citations

361413

20
h-index

361022

35
g-index

35
all docs

35
docs citations

35
times ranked

2179
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2854-2865.	6.7	159
2	Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. <i>Cancer Biology and Therapy</i> , 2008, 7, 1212-1225.	3.4	136
3	Caveolin-1 Deficiency Increases Cerebral Ischemic Injury. <i>Circulation Research</i> , 2007, 100, 721-729.	4.5	125
4	Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy. <i>Circulation</i> , 2006, 114, 912-920.	1.6	96
5	Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment. <i>American Journal of Pathology</i> , 2012, 181, 278-293.	3.8	95
6	Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. <i>Cardiovascular Research</i> , 2004, 63, 747-755.	3.8	79
7	Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. <i>Laboratory Investigation</i> , 2009, 89, 614-623.	3.7	76
8	Caveolin-1 Deficiency Stimulates Neointima Formation during Vascular Injury. <i>Biochemistry</i> , 2004, 43, 8312-8321.	2.5	73
9	Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. <i>Cardiovascular Research</i> , 2003, 58, 621-631.	3.8	68
10	Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. <i>Cell Cycle</i> , 2009, 8, 1654-1658.	2.6	64
11	Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions. <i>American Journal of Pathology</i> , 2009, 174, 1172-1190.	3.8	57
12	ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. <i>Cell Cycle</i> , 2008, 7, 1640-1647.	2.6	50
13	SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 150-158.	7.1	47
14	Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H1274-H1281.	3.2	46
15	Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. <i>Cell Cycle</i> , 2013, 12, 1510-1520.	2.6	45
16	Genetic ablation of caveolin-1 increases neural stem cell proliferation in the subventricular zone (SVZ) of the adult mouse brain. <i>Cell Cycle</i> , 2009, 8, 3978-3983.	2.6	32
17	CAPER, a novel regulator of human breast cancer progression. <i>Cell Cycle</i> , 2014, 13, 1256-1264.	2.6	24
18	Caveolin-2-deficient mice show increased sensitivity to endotoxemia. <i>Cell Cycle</i> , 2011, 10, 2151-2161.	2.6	23

#	ARTICLE	IF	CITATIONS
19	Glutamine Supplementation Alleviates Vasculopathy and Corrects Metabolic Profile in an In Vivo Model of Endothelial Cell Dysfunction. PLoS ONE, 2013, 8, e65458.	2.5	23
20	Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clinical Science, 2006, 111, 217-224.	4.3	22
21	Development of a High-Affinity Inhibitor of the Prostaglandin Transporter. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 633-641.	2.5	22
22	Cardiac resident nestin ⁺ cells participate in reparative vascularisation. Journal of Cellular Physiology, 2013, 228, 1844-1853.	4.1	22
23	Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. Journal of Cellular Physiology, 2015, 230, 170-179.	4.1	19
24	Nestin Expressed by Pre-Existing Cardiomyocytes Recapitulated in Part an Embryonic Phenotype; Suppressive Role of p38 MAPK. Journal of Cellular Physiology, 2017, 232, 1717-1727.	4.1	18
25	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. International Journal of Biochemistry and Cell Biology, 2011, 43, 1318-1329.	2.8	16
26	Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimoziide treatment in triple-negative breast cancer. Cancer Biology and Therapy, 2020, 21, 506-521.	3.4	16
27	Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and to predict the Caveolin-1 (P132L) mutation. Cell Cycle, 2009, 8, 1396-1401.	2.6	15
28	Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell and Tissue Research, 2014, 358, 821-831.	2.9	15
29	Development of CAPER peptides for the treatment of triple negative breast cancer. Cell Cycle, 2020, 19, 432-447.	2.6	14
30	Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury. Cell Cycle, 2013, 12, 2248-2254.	2.6	10
31	Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice. PLoS ONE, 2015, 10, e0131735.	2.5	10
32	Mesenchymal Stem Cells, Used As Bait, Disclose Tissue Binding Sites. American Journal of Pathology, 2010, 177, 873-883.	3.8	9
33	CAPER as a therapeutic target for triple negative breast cancer. Oncotarget, 2018, 9, 30340-30354.	1.8	9
34	Essential role of STAT5a in DCIS formation and invasion following estrogen treatment. Aging, 2020, 12, 15104-15120.	3.1	3
35	Chapter 11 Caveolin Proteins in Cardiopulmonary Disease and Lung Cancers. Advances in Molecular and Cell Biology, 2005, , 211-233.	0.1	2